UPADACITINIB
Information current as at: 1 April 2024
Submission Details
- Brand name:
-
- Rinvoq®
- Pharmaceutical company:
- Abbvie Pty Ltd
- Condition/indication:
(therapeutic use) -
- Psoriatic arthritis
- PBAC Submission type:
- Change to listing (Major Submission)
- Comment:
- --
- Public Summary Document:
- PBAC Public Summary Documents – March 2021
- Related medicines:
- --
Progress Details
-
Submission received for: - March 2021 PBAC meeting
-
Opportunity for consumer comment: - Open 23/12/2020 and close 10/02/2021 (see PBS Website)
-
PBAC meeting: - Held on 10/03/2021
-
Lodgement of required documentation: - 12/05/2021
-
Acceptance of complete documentation:
- Accepted
-
Agreement to listing arrangements: - Commenced on 28/05/2021
-
Status:
- Finalised
-
Government processes: - Commenced on 22/06/2021
-
Medicine listed on the PBS: - 01/10/2021 (see PBS schedule)
Case ID: a324
Page last updated: 04 April 2024